Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 6/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9908998 | 1.00 | NR1H2 (0.43) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL12691441 | 0.92 | NR1H2 (0.40) | NR1H2TACR1MEN1KMT2A | |
| SCHEMBL4405469 | 0.90 | NR1H2 (0.40) | NR1H2TACR1MEN1KMT2A | |
| SCHEMBL30484634 | 0.87 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL30484632 | 0.87 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL13305539 | 0.85 | BRD4 (0.34) | NR1H2CHRM2CHRM1CHRM3DDB1 | |
| SCHEMBL24909178 | 0.84 | NR1H2 (0.42) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL12691702 | 0.82 | NR1H2 (0.33) | NR1H2TACR1MEN1KMT2ACHRM2 | |
| SCHEMBL14870488 | 0.81 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL4308762 | 0.81 | CHRM2 (0.38) | NR1H2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324060-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324060-A1 | PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HCV | HAVCR2, LIPC, CPT1A | NR1H2 50/4885TACR1 467/4885MEN1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.